Ranbaxy introduces Atorvastatin-Amlodipine besylate tablets in the U.S.

Dec 6 2011

Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE: 500359) ("Ranbaxy"), has launched an authorized generic version of Caduet® in the U.S. market, as part of an agreement with Pfizer Inc.

Caduet® is a fixed-dose combination of Atorvastatin-Amlodipine besylate (presently marketed by Pfizer under the brand Caduet®, which also contains a crystalline form of Atorvastatin). The product is indicated for patients suffering from both, high blood pressure and high levels of cholesterol. Caduet® generated total annual sales of $339 million in the U.S. (IMS - MAT September 2011).

Ranbaxy is making available the full range of the generic version of Caduet®.

Mr. Venkat Krishnan, Sr. Vice President & Regional Director, Americas, Ranbaxy, said, "The introduction of Atorvastatin-Amlodipine besylate tablets is a significant and important addition to our portfolio of cardio-vascular products, in the U.S. The launch further complements our resolve to bring high quality, affordable generic medicines as early as possible to the U.S. healthcare system, benefitting a wider cross-section of people."

Source: Ranbaxy Pharmaceuticals Inc.